Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DFTX
DEFINIUM THERAPEUTICS, INC.
NASDAQ
$40.98
▼ DOWN 6.48% (-2.84)

KEY STATISTICS

Market Cap$5.44 B
52w High$49.20
52w Low$12.88
Dividend Yield—
Frequency—
P/E—
Volume1.80M
Shares Out.—

COMPANY

LEADERSHIP

Robert Barrow
CHIEF EXECUTIVE
Robert Barrow

COMPENSATION 2026

Salary$655,000
Stock Awards$11,719,750
Incentive Plan Pay$378,263
All Other Comp.$14,429
Total$12,767,442

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 15, 2016
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
106

PRICE TARGET

Target High$75.00
Target Low$52.00
Target Median$66.00
Target Consensus$64.90

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2022-08-29Reverse1:15
2020-03-03Reverse1:8

PRICE

$40.98 ▼ DOWN 6.48% (−$2.84)
OVERLAYS
$41.25$42.00$42.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM40.98

About Definium Therapeutics, Inc.

https://definiumtx.com ↗

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel brain health treatments, with lead candidates MM120 for anxiety and ADHD in phase 3, and MM402 for autism spectrum disorder in phase I.

INDUSTRY

Biotechnology

A PRODUCT DEFINIUM THERAPEUTICS, INC. IS KNOWN FOR

DT120 ODT
DT120 ODT

DT120 ODT, a lysergide (LSD) D-tartrate orally disintegrating tablet by Definium Therapeutics, is in late-stage Phase 3 trials for GAD and MDD, with FDA Breakthrough Therapy Designation for GAD.

COMPETITORS

COMPETITOR
ANRO COMPARE
ATAI COMPARE
CMPS COMPARE
GHRS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
89
LISTED HERE
21
RANKED BY POSITION SIZE
IWM
0.18% · 3.3M
VXF
0.07% · 1.5M
SCHA
0.12% · 614.8K
FESM
0.27% · 409.5K
XPH
2.68% · 358.8K
CGMM
0.37% · 314.5K
PSIL
10.89% · 149.6K
SBIO
2.28% · 134.5K
NUSC
0.28% · 98.9K
GSC
1.19% · 76.8K
RSSL
0.18% · 62.1K
FRTY
1.03% · 37.6K
PRFZ
0.02% · 14.4K
BBC
1.06% · 12.7K
MMSC
0.92% · 11.1K
PILL
1.80% · 10.1K
URTY
0.07% · 5.3K
BKSE
0.21% · 4.7K
RFLR
0.19% · 4.4K
ASD
4.06% · 1.4K
TNXT
0.20% · 840

INSTITUTIONAL OWNERSHIP

SHARES OWNED
—
HOLDERS
365
TOP 12 OF 365 · RANKED BY POSITION SIZE
Blackrock, Inc.
11.2M sh · $528.39M
Avoro Capital Advisors LLC
7.2M sh · $338.17M
Driehaus Capital Management LLC
6.8M sh · $322M
Capital World Investors
5.4M sh · $252.5M
Fmr LLC
4.8M sh · $223.58M
Price T Rowe Associates Inc /Md/
4.7M sh · $218.83M
Geode Capital Management, LLC
3.6M sh · $171.48M
State Street Corp
3.1M sh · $144.2M
Deep Track Capital, LP
3.0M sh · $56.7M
Capital International Investors
3.0M sh · $139.4M
Octagon Capital Advisors LP
3.0M sh · $138.77M
Wellington Management Group Llp
2.9M sh · $138.76M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Barrow Robert
Purchase · 375.0K shares
2026-08-12
★
OFFICER: CHIEF MEDICAL OFFICER
Karlin Daniel
Purchase · 100.0K shares
2026-08-12
★
OFFICER: CHIEF LEGAL OFFICER
Sullivan Mark
Purchase · 62.5K shares
2026-08-12
★
OFFICER: CHIEF FINANCIAL OFFICER
Roberts Brandi
Purchase · 62.5K shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 4
OVERWEIGHT 2
12 GRADES IN THE LAST 12 MONTHS
Maxim Group BUY Canaccord Genuity BUY Jones Trading BUY Baird OUTPERFORM RBC Capital OUTPERFORM Wells Fargo OVERWEIGHT Needham BUY Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
FTRE$18.81COMPARE
ANAB$56.28COMPARE
SVRA$5.26COMPARE